JiÅÃM KlimeÅ;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2733842/publications.pdf

Version: 2024-02-01

	471509	642732
836	17	23
citations	h-index	g-index
/3	/3	888
docs citations	times ranked	citing authors
	citations 73	836 17 citations h-index 73 73

#	Article	IF	CITATIONS
1	Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD—A Cost-Effectiveness Analysis in the Czech Republic. Value in Health Regional Issues, 2018, 16, 112-118.	1.2	3
2	Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. European Journal of Health Economics, 2017, 18, 73-82.	2.8	10
3	A model of natural degradation of 17-α-ethinylestradiol in surface water and identification of degradation products by GC-MS. Environmental Science and Pollution Research, 2017, 24, 23196-23206.	5.3	5
4	Stability Indicating Method for Determination of Sodium Picosulfate in Pharmaceutical Preparation – Comparison of HPLC, UHPLC and HTLC. Current Pharmaceutical Analysis, 2017, 13, 250-255.	0.6	1
5	Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs). Xenobiotica, 2016, 46, 416-423.	1.1	1
6	Solid-Phase Extraction of Ibuprofen from Pharmaceuticals via Ligand Exchange Using Zirconium Dioxide. Current Analytical Chemistry, 2016, 12, 523-528.	1.2	3
7	Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro. Biochemical Pharmacology, 2015, 98, 465-472.	4.4	27
8	LC–UV/MS methods for the analysis of prochelator—Boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 55-63.	2.8	13
9	Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of-Illness Study Based on Disease Severity. Value in Health Regional Issues, 2014, 4, 75-81.	1.2	15
10	Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis. Value in Health Regional Issues, 2014, 4, 100-106.	1.2	16
11	Zirconia-A stationary phase capable of the separation of polar markers of myocardial metabolism in hydrophilic interaction chromatography. Journal of Separation Science, 2014, 37, 1089-1093.	2.5	9
12	Simultaneous determination of the novel thiosemicarbazone antiâ€cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomedical Chromatography, 2014, 28, 621-629.	1.7	7
13	Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography–quadrupole-time-of-flight mass spectrometry. Analytical and Bioanalytical Chemistry, 2013, 405, 1651-1661.	3.7	6
14	Development of LC–MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium. Journal of Pharmaceutical and Biomedical Analysis, 2013, 76, 243-251.	2.8	9
15	Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1). PLoS ONE, 2013, 8, e75520.	2.5	6
16	The Retention Behavior of Acidic, Basic and Neutral Pharmaceuticals on the Deactivated Polybutadiene Zirconia Phase. Current Analytical Chemistry, 2012, 8, 574-582.	1.2	1
17	Identification of Pavinane Alkaloids in the Genera Argemone and Eschscholzia by GC-MS. Natural Product Communications, 2012, 7, 1934578X1200701.	0.5	4
18	Alkaloids from Some Amaryllidaceae Species and Their Cholinesterase Activity. Natural Product Communications, 2012, 7, 1934578X1200700.	0.5	7

#	Article	IF	CITATIONS
19	LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT. Analytical and Bioanalytical Chemistry, 2012, 403, 309-321.	3.7	16
20	The influence of a carbon layer deposited on a zirconia surface on the retention of polar analytes in an organic rich mobile phase. Journal of Chromatography A, 2012, 1232, 242-247.	3.7	6
21	The retention behaviour of polar compounds on zirconia based stationary phases under hydrophilic interaction liquid chromatography conditions. Journal of Chromatography A, 2011, 1218, 6981-6986.	3.7	29
22	Use of different stationary phases for separation of isoniazid, its metabolites and vitamin B6 forms. Journal of Separation Science, 2011, 34, 1357-1365.	2.5	12
23	Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites—the cardioprotectant dexrazoxane as a model case. Journal of Chromatography A, 2011, 1218, 416-426.	3.7	18
24	HPLC analysis of a syrup containing nimesulide and its hydrolytic degradation product. Chemical Papers, 2010, 64, .	2.2	2
25	Development of an LC–MS/MS method for analysis of interconvertible Z/E isomers of the novel anticancer agent, Bp4eT. Analytical and Bioanalytical Chemistry, 2010, 397, 161-171.	3.7	10
26	An innovative approach to the analysis of 3-[4-(2-methylpropyl)phenyl]propanoic acid as an impurity of ibuprofen on a carbon-coated zirconia stationary phase. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 1150-1156.	2.8	6
27	Development and Validation of an LC–ESI-MS Ion-Trap Method for Analysis of Impurities in Transkarbam 12, a Novel Transdermal Accelerant. Chromatographia, 2009, 69, 977-983.	1.3	2
28	RP-ZrO2 Stationary Phase as an Alternative to Separate of Doxazosin Impurities. Chromatographia, 2009, 70, 185-189.	1.3	2
29	HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and) Tj ETQq1 Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 316-322.	l 0.784314 rgBT 2.3	
30	HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 295-302.	2.8	23
31	Determination of lipophilicity of novel potential antituberculotic agents using HPLC on monolithic stationary phase and theoretical calculations. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 310-314.	2.8	17
32	Investigation of the stability of aromatic hydrazones in plasma and related biological material. Journal of Pharmaceutical and Biomedical Analysis, 2008, 47, 360-370.	2.8	35
33	Titania-based stationary phase in separation of ondansetron and its related compounds. Journal of Chromatography A, 2008, 1189 , $83-91$.	3.7	19
34	Isolation and identification of amphetamines in urine by thin-layer chromatography. Journal of Planar Chromatography - Modern TLC, 2008, 21, 465-468.	1.2	1
35	Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1343-1351.	2.8	11
36	Potential employment of non-silica-based stationary phases in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis, 2007, 44, 1048-1055.	2.8	11

#	Article	IF	CITATIONS
37	High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 853, 265-274.	2.3	37
38	Using of HPLC coupled with coulometric detector for the determination of biotin in pharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis, 2007, 45, 730-735.	2.8	11
39	HPLC study on stability of pyridoxal isonicotinoyl hydrazone. Journal of Pharmaceutical and Biomedical Analysis, 2006, 40, 105-112.	2.8	18
40	Optimization of HPLC chromatographic conditions for determination of Transkarbam 12 and its degradation products. Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 136-142.	2.8	5
41	HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 838, 107-112.	2.3	14
42	Preliminary pharmaceutico-analytical evaluation of Transkarbam 12 using liquid chromatography. Journal of Separation Science, 2006, 29, 1595-1599.	2.5	3
43	Comparison of different stationary phases for bioanalytical studies of biologically active compounds. Journal of Separation Science, 2006, 29, 2126-2135.	2.5	3
44	Determination of the lipophilicity of potential antituberculotic compounds by RP-TLC. Journal of Planar Chromatography - Modern TLC, 2006, 19, 422-426.	1.2	10
45	Disposition study of a new potential antineoplastic agent dimefluron in rats using high-performance liquid chromatography with ultraviolet and mass spectrometric detection. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 1059-1071.	2.8	12
46	Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 1049-1057.	2.8	6
47	Stability of ramipril in the solvents of different pH. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 1179-1183.	2.8	18
48	Use of the zirconia-based stationary phase for separation of ibuprofen and its impurities. Journal of Pharmaceutical and Biomedical Analysis, 2005, 38, 609-618.	2.8	14
49	Utilization of zirconia stationary phase as a tool in drug control. Journal of Separation Science, 2005, 28, 1307-1314.	2.5	9
50	Development of high-performance liquid chromatographic determination of salicylaldehyde isonicotinoyl hydrazone in rabbit plasma and application of this method to anin vivo study. Journal of Separation Science, 2005, 28, 1300-1306.	2.5	31
51	Reversed-phase thin-layer chromatographic determination of the lipophilicity of potential antituberculotic compounds. Journal of Planar Chromatography - Modern TLC, 2005, 18, 450-454.	1.2	7
52	Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron chelates. Journal of Separation Science, 2004, 27, 1503-1510.	2.5	12
53	HPLC study of glimepiride under hydrolytic stress conditions. Journal of Pharmaceutical and Biomedical Analysis, 2004, 36, 205-209.	2.8	38
54	Reversedâ€Phase High Performance Liquid Chromatographic Determination of Lipophilicity of Potential Antituberculosis Compounds. Journal of Liquid Chromatography and Related Technologies, 2004, 27, 2539-2545.	1.0	5

#	Article	IF	CITATIONS
55	Photochemical stability of nimesulide. Journal of Pharmaceutical and Biomedical Analysis, 2003, 31, 827-832.	2.8	18
56	LIPOPHILICITY CHARACTERIZATION BY REVERSED-PHASE HPLC OF POTENTIAL ANTITUBERCULOTICS. Journal of Liquid Chromatography and Related Technologies, 2002, 25, 2849-2856.	1.0	4
57	A study of the conditions of the supercritical fluid extraction in the analysis of selected anti-inflammatory drugs in plasma. Il Farmaco, 2002, 57, 117-122.	0.9	7
58	Study of the lipophilicity of potential antituberculotic compounds by reversed-phase thin-layer chromatography. Journal of Planar Chromatography - Modern TLC, 2002, 15, 200-203.	1.2	10
59	HPLC evaluation of diclofenac in transdermal therapeutic preparations. International Journal of Pharmaceutics, 2001, 217, 153-160.	5.2	22
60	DETERMINATION OF LIPOPHILICITY OF POTENTIAL ANTITUBERCULOUS DRUGS BY REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. Journal of Liquid Chromatography and Related Technologies, 2001, 24, 2257-2265.	1.0	4
61	Reversed-phase thin-layer chromatographic determination of the lipophilicity of potential antituberculotic compounds. Journal of Planar Chromatography - Modern TLC, 2001, 14, 291-295.	1.2	7
62	Combination of molecular modeling and quantitative structure–activity relationship analysis in the study of antimycobacterial activity of pyridine derivatives. International Journal of Pharmaceutics, 2000, 207, 1-6.	5.2	16
63	HPLC ANALYSIS OF TIAPROFENIC ACID IN THE SAMPLES OF WHOLE BLOOD USING L-L AND S-L EXTRACTIONS. Journal of Liquid Chromatography and Related Technologies, 2000, 23, 3191-3201.	1.0	2
64	Microcolumn high-performance liquid chromatographic assay for doxycycline in isolated alveolar macrophages. Journal of Chromatography A, 1999, 846, 181-184.	3.7	11
65	Relationship between structure and reversed-phase thin-layer chromatographic lipophilicity parameters in a group of piperazine derivatives. Journal of Chromatography A, 1997, 766, 165-170.	3.7	13
66	High-performance liquid chromatographic determination of terguride in solid dosage forms and plasma. Biomedical Applications, 1995, 663, 309-313.	1.7	3
67	Determination of ibuprofen in erythrocytes and plasma by high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 1995, 13, 899-903.	2.8	34
68	High-Performance Liquid Chromatographic Analysis of Kebuzone and Its Metabolites in the Samples of Erythrocytes, Plasma, and Whole Blood. Journal of Liquid Chromatography and Related Technologies, 1995, 18, 2147-2166.	1.0	0
69	High-performance liquid chromatographic assay for ibuprofen in whole blood using solid-phase extraction. Biomedical Applications, 1994, 654, 282-286.	1.7	13
70	Relations between Structure and Antituberculotic Activity of 4-Alkoxybenzoic Acids. Collection of Czechoslovak Chemical Communications, 1993, 58, 191-196.	1.0	7
71	Chromatographic behaviour of dipyridylsulphides Relationship between log $k\hat{a}\in^2$ values and structure by reversed-phase high-performance liquid chromatography. Journal of Chromatography A, 1992, 595, 334-336.	3.7	8
72	Simultaneous high-performance liquid chromatographic determination of salicylates in whole blood, plasma and isolated erythrocytes. Biomedical Applications, 1992, 584, 221-228.	1.7	22